Back to Search
Start Over
Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma.
Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma.
- Source :
-
European journal of cancer & clinical oncology [Eur J Cancer Clin Oncol] 1983 Apr; Vol. 19 (4), pp. 499-506. - Publication Year :
- 1983
-
Abstract
- Patients with newly diagnosed multiple myeloma were randomly allotted to an intermittent high-dose melphalan/prednisone (MP) treatment (120 patients) or a continuous low-dose melphalan (M) regimen (99 patients). The median observation time was 59 months (range 33-84). Response to therapy was obtained in 45% of the MP group and 31% of the M group (P less than 0.05). No significant difference in response with regard to clinical stage was noted. Median survival was 36 months in the MP group and 29 months in the M group. Survival was longer in stage I and II myeloma than in the stage III cases, at least in the MP group. The median and 5-yr survival rates in stages I and II were significantly better in the MP than in the M group. Response to therapy was associated with length of survival, median survival being 62 months in responding patients and 20 months in non-responders. The MP and M groups did not differ in this respect.
- Subjects :
- Adult
Age Factors
Aged
Clinical Trials as Topic
Drug Administration Schedule
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Multiple Myeloma mortality
Multiple Myeloma pathology
Neoplasm Staging
Prospective Studies
Melphalan administration & dosage
Multiple Myeloma drug therapy
Prednisone administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 0277-5379
- Volume :
- 19
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- European journal of cancer & clinical oncology
- Publication Type :
- Academic Journal
- Accession number :
- 6345174
- Full Text :
- https://doi.org/10.1016/0277-5379(83)90113-x